Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents

University of California, Los Angeles (UCLA)

Status: Active, not recruiting

Conditions: Hypertension, Portal; Ascites

Treatments: Procedure: Large Volume Paracentesis with albumin infusion; Device: Gore® Viatorr® Endoprosthesis with controlled expansion

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04315571

CXTIPSvLVP-v1

Details and patient eligibility

About

For this study, the investigators will be collecting data based on patients' random selection to two different approved standard of care treatments for ascites: Subjects will get randomized into either Group A: Large Volume Paracentesis (LVP) with albumin infusion, or Group B: an early transjugular intrahepatic portosystemic shunt (TIPS) procedure.

Full description

End Stage Liver Disease (ESLD) severely impacts body function leading to elevated blood pressure within the liver called "portal hypertension." One of its subsequent symptoms is ascites, or fluid accumulation in the abdomen. One standard treatment to relieve ascites is large volume paracentesis (puncture of the abdomen to drain the fluid). Another standard treatment is the TIPS procedure, which involves creating a shunt (small passage allowing fluid movement) within the liver to relieve the increased blood pressure in the liver.

For this study, the investigators will be collecting data based on patients' random selection to two different approved standard of care treatments for ascites: Subjects will get randomized into either Group A: Large Volume Paracentesis (LVP) with albumin infusion, or Group B: an early transjugular intrahepatic portosystemic shunt (TIPS) procedure.

The study will include about 68 patients (34 patients will be selected for Group A: continuing conservative treatment of LVP with albumin infusion, and 34 patients will be selected for Group B: undergoing early TIPS with Gore®Viatorr®CX). Each patient will be followed up at 1 month, 3 months, 6 months, and 12 months.

The primary objective of this study is to evaluate the overall clinical efficacy in symptom relief of ascites of patients receiving the Gore® Viatorr® CX in early TIPS procedures compared to LVP (large volume paracenthesis). In order to so, the investigators will be using information found in patient medical records, collected as a part of standard of care, to analyze clinical outcomes, complications, and the rate of secondary interventions at follow-up.

Enrollment: 68 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males and females > 18 years of age at time of procedure

• First de novo TIPS placement

• Patent internal or external jugular vein

• Willing to provide the hepatology service information for follow up

• No known diagnosis of hypercoagulopathy

• No portal vein thrombosis

• No malignancy (must be a definite diagnosis)

• Patient must provide written informed consent

• Proper clinical indication of TIPS based on American Association for the Study of Liver Diseases (AASLD) guidelines

  • Recurrent ascites necessitating at least 2 large volume paracenteses performed within a minimum interval of 3 weeks

Exclusion criteria

• Age <18
• LVP > 6 times in 2 months
• Liver failure (Child Pugh > 12)
• Cardiac failure
• No right jugular venous access
• Absolute TIPS contraindications (e.g. right heart failure, severe encephalopathy, liver failure, pregnant (if possible)).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

68 participants in 2 patient groups

Group A

Active Comparator group

Description:

Routine Large Volume Paracentesis (LVP) with albumin infusion

Treatment:

Procedure: Large Volume Paracentesis with albumin infusion

Group B

Active Comparator group

Description:

Early Transjugular intrahepatic portosystemic shunt (TIPS) procedure using Gore Viatorr CX

Treatment:

Device: Gore® Viatorr® Endoprosthesis with controlled expansion